Evolent Health, Inc. (EVH)
NYSE: EVH · IEX Real-Time Price · USD
21.19
-0.34 (-1.58%)
May 31, 2024, 4:00 PM EDT - Market closed
Evolent Health Revenue
Evolent Health had revenue of $2.18B in the twelve months ending March 31, 2024, with 46.76% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $639.65M with 49.56% year-over-year growth. In the year 2023, Evolent Health had annual revenue of $1.96B with 45.26% growth.
Revenue (ttm)
$2.18B
Revenue Growth
+46.76%
P/S Ratio
1.13
Revenue / Employee
$462,949
Employees
4,700
Market Cap
2.46B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.96B | 611.88M | 45.26% |
Dec 31, 2022 | 1.35B | 444.06M | 48.91% |
Dec 31, 2021 | 907.96M | -16.68M | -1.80% |
Dec 31, 2020 | 924.64M | 237.52M | 34.57% |
Dec 31, 2019 | 687.12M | 60.06M | 9.58% |
Dec 31, 2018 | 627.06M | 192.11M | 44.17% |
Dec 31, 2017 | 434.95M | 180.76M | 71.11% |
Dec 31, 2016 | 254.19M | 157.31M | 162.38% |
Dec 31, 2015 | 96.88M | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 25.67M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 8.97B |
Integra LifeSciences Holdings | 1.53B |
Indivior | 1.12B |
ACADIA Pharmaceuticals | 813.81M |
NovoCure | 525.66M |
TG Therapeutics | 289.33M |
Twist Bioscience | 277.49M |
Immunocore Holdings | 264.25M |
EVH News
- 23 days ago - Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S. - PRNewsWire
- 23 days ago - Evolent Announces First Quarter 2024 Results - PRNewsWire
- 6 weeks ago - Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 - PRNewsWire
- 3 months ago - Evolent Announces Fourth Quarter and Full Year 2023 Results - PRNewsWire
- 3 months ago - Evolent Adds Russell Glass, Headspace CEO, to Board of Directors - PRNewsWire
- 4 months ago - Evolent to Release Fourth Quarter 2023 Financial Results on Thursday, February 22, 2024 - PRNewsWire
- 6 months ago - Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan - PRNewsWire
- 6 months ago - Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan - PRNewsWire